What our clients say Discover inspirational transformation stories from real Agile Telehealth members
Roche to present new data advancing its obesity portfolio at the American Diabetes Associations 2026 Scientific Sessions 2026-06-01 Late-breaking Phase II data highlight enicepatides (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintides efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity A Phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated towards mid-2026 to develop a differentiated treatment option Basel, 1 June 2026 - Roche (SIX: RO, ROP
Mechanism of Action Incretins hormones like GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are released throughout the day, increasing at mealtimes
We are biologically wired
However, vitamin A levels significantly increased after 2 hours of liposomal MVM ingestion, with no significant changes observed among treatments
Wegovy injection is administered subcutaneously using a pen injector